Forest Laboratories’ Solomon May Be Barred From U.S. Programs

Forest Laboratories Inc. Chairman and Chief Executive Officer Howard Solomon, whose company paid $313 million to settle a U.S. fraud case last year, is the latest pharmaceutical executive facing a ban from doing business with federal health programs.

To continue reading this article you must be a Bloomberg Professional Service Subscriber.